Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds
Biotechnology Veteran David Hung, M.D. Launches Stealth Start-Up Focusing on the Foremost Unmet Needs in Oncology Nuvation Bio's Proprietary Portfolio Includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A